One big dose may beat many: new palliative radiotherapy trial
NCT ID NCT04649125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a single, higher-dose palliative radiotherapy session to the usual 5-10 sessions for people with metastatic cancer. The goal is to see if one strong dose can keep symptoms away longer, up to 12 months. About 100 participants will be enrolled to measure how long the benefit lasts and how practical the single-dose approach is.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2021
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Metastatic cancer * Recommended for 5-10 fractions palliative radiation * Patients with spinal cord compression are eligible for enrolment Exclusion Criteria: * Unwilling or unable to give informed consent * Patients who are recommended for single fraction palliative radiation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Royal North Shore Hospital
RECRUITINGSaint Leonards, New South Wales, 2065, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug targets Sugar-Coated proteins on cancer cells
- Zapping a few growing tumors may keep breast cancer drugs working longer
- Can a platform trial match the right drug combo to each tumor?
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Can a new antibody outsmart advanced solid tumors?
- Tissue analysis may guide personalized cancer therapy